SCH 727965 + Bortezomib + Alemtuzumab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Trial Timeline
Mar 1, 2009 → Dec 1, 2010
NCT ID
NCT00871546About SCH 727965 + Bortezomib + Alemtuzumab
SCH 727965 + Bortezomib + Alemtuzumab is a phase 2 stage product being developed by Merck for Lymphoma, Mantle-Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT00871546. Target conditions include Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Mantle-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00871546 | Phase 2 | Terminated |
Competing Products
20 competing products in Lymphoma, Mantle-Cell